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Abstract
Atherosclerosis is characterized by a chronic inflammatory disease, and chemokines play an important role in both initiation and progression of
atherosclerosis development. Leukotactin-1 (Lkn-1/CCL15), a new member of the human CC chemokine family, is a potent chemoattractant for 
leukocytes. Our previous study has demonstrated that Lkn-1/CCL15 plays a role in the initiation of atherosclerosis, however, little is currently known
whether Lkn-1/CCL15 is associated with the progression of atherosclerosis. Matrix metalloproteinases (MMPs) in human coronary atherosclerotic
lesions play a crucial role in the progression of atherosclerosis by altering the vulnerability of plaque rupture. In the present study, we examined 
whether Lkn-1/CCL15 modulates MMP-9 release, which is a prevalent form expressed by activated macrophages and foam cells. Human THP-1 
monocytic cells and/or human peripheral blood monocytes (PBMC) were treated with phorbol myristate acetate to induce their differentiation into
macrophages. Foam cells were prepared by the treatment of THP-1 macrophages with human oxidized LDL. The macrophages and foam cells were
treated with Lkn-1/CCL15, and the levels of MMP-9 release were measured by Gelatin Zymography. Lkn-1/CCL15 significantly enhanced the levels
of MMP-9 protein secretion from THP-1 monocytic cells-derived macrophages, human PBMC-derived macrophages, as well as macrophage-derived
foam cell in a dose dependent manner. Our data suggest that the action of Lkn-1/CCL15 on macrophages and foam cells to release MMP-9 may
contribute to plaque destabilization in the progression of atherosclerosis. 
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Early atherogenesis is characterized by the recruitment of 
circulating leukocytes (e.g., monocytes/macrophages and T-lym-
phocytes etc.) into artery wall, the formation of foam cells in 
the vessel intima, leading to the development of atherosclerotic 
lesions. The inflammatory responses in the atherosclerotic lesions 
play a crucial role to promote plaque rupture and thrombosis 
in the late progression of atherosclerosis, leading to myocardial 
infarction and strokes (Libby, 2002). The rupture-prone plaque 
is featured by a large lipid core and accumulation of infla-
mmatory cells including macrophages and T-lymphocytes (Mann 
& Davies, 1996). A family of matrix metalloproteinases (MMPs), 
which are proteolytic enzymes secreted by the inflammatory 
cells, play a pivotal role in degrading extracellular matrix and 
plaque rupturing (Newby, 2005). 
Chemokines, a superfamily of chemotactic cytokines, not only 
cause the recruitment of leukocytes into the arterial wall, but 
also influence atherosclerotic plaque stability by enhancing 
MMPs releases (Reape & Groot, 1999; Sheikine & Hansson, 
2004), and thus play a crucial role in both the initiation and 
the progression of atherosclerosis. Leukotactin-1 (Lkn-1/CCL15), 
a new member of the human CC chemokine family, is a potent 
chemoattractant for leukocytes, and it is implicated in inf-
lammatory pathologies including atherosclerosis. Our previous 
study and others have shown that the levels of Lkn-1/CCL15 
expression are markedly up-regulated in macrophage-derived 
foam cells and in human atherosclerotic lesions (Lee et al., 2002; 
Yu  et al., 2004), and moreover, the proatherogenic mediators 
such as oxidized lipoprotein and oxidative stress markedly 
upregulte Lkn-1/CCL15 gene expression and protein release from 
the foam cells (Yu et al., 2004), indicating Lkn-1/CCL15 plays 
a role in the initiation of atherogenesis. However, it remains 
unclear whether Lkn-1/CCL15 is associated with the progression 
of atherosclerosis. 
In the present study, we investigated whether Lkn-1/CCL15 
can enhance MMP-9 release from macrophages and/or foam cells, 
which influence plaque rupture. Our data demonstrated that 
Lkn-1/CCL15 enhanced MMP-9 protein release from human 
macrophages and macrophage-derived foam cells, indicating that 
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Lkn-1/CCL15 may be associated with the vulnerability of plaque 
rupture in the late stage of atherosclerosis.
Materials and methods
Cell culture
THP-1 cells were obtained from the Korean Cell Line Bank. 
THP-1 monocytes were maintained in the RPMI-1640 medium 
(Gibco). The cells were plated at a density of 5 × 10
5  cells/ml 
in the medium containing phorbol myristate acetate (PMA, 
Sigma) at 10
-7  M for 48 h to induce their differentiation into 
macrophages. 
Preparation of human peripheral blood monocytes (PBMCs) and 
culture
Peripheral blood was collected from healthy donors. Peripheral 
blood mononuclear cells were separated on a Histopaque-1077 
gradient. After washings twice with HBSS without Ca
2+ and 
Mg
2+, the PBMCs were then suspended in 10% FBS containing 
RPMI and incubated for 60 min at 37℃ to let the monocytes 
attach to the culture dish. The attached monocytes were harvested 
by vigorous pipetting and plated at a density of 5 × 10
5  cells/ml 
in the medium containing PMA at 10
-7  M for 48 h to induce 
their differentiation into macrophages. 
Preparation of oxidized LDL 
Human low density lipoprotein (LDL) (d = 1.006-1.063) was 
separated from freshly drawn normal plasma sample by 
sequential ultracentrifugation and extensively dialyzed at 4℃ 
against 0.15 mol/L NaCl and 0.01% EDTA. After EDTA was 
removed, LDL was subjected to oxidative modification by 
incubation with Cu
2+ (5 μM CuSO4, 16 h at 37℃). Then Cu
2+ 
was removed by extensive dialysis (Yu et al., 2004). The extent 
of modification was assessed by the determination of electro-
phoretic mobility on agarose gels. In agarose gel electrophoresis, 
oxidized LDL (oxLDL) moved two to three times faster than 
LDL did. OxLDL was stored at 4 ◦C and was used within 4 
weeks of preparation. 
Foam cell formation
To prepare macrophage-derived foam cells, human THP-1 cells 
were plated at a density of 5 × 10
5 cells/ml in the medium 
containing PMA at 10
-7M for 48 h to induce their differentiation 
into macrophages, and then the cells were treated with human 
oxidized LDL (25 μg/ml) for 4 days (Yu et al., 2004). 
Gelatin zymography 
The gelatinolytic activities of MMP-9 in the conditioning 
culture medium were assayed by electrophoresis on 10% 
polyacrylamide gels containing 1 mg/ml gelatin at 4℃. PAGE 
gels were run at 120 V, washed in 2.5% Triton X-100 for 1 
h, and then incubated for 16 h at 37℃ in activation buffer (50 
mM Tris-HCl, pH 7.5, 10 mM CaCl2). After staining with 
Coomassie blue (10% glacial acetic acid, 30% methanol and 
1.5% Coomassie brilliant blue) for 2-3 h, the gel was destained 
with a solution of 10% glacial acetic acid, and 30% methanol 
without Coomassie blue for 1 h. White lysis zones indicating 
gelatin degradation were revealed by staining with Coomassie 
brilliant blue R-250.
Results and Discussion
The present study has demonstrated that Lkn-1/CCL15 
enhances MMP-9 protein release by macrophages and macro-
phages-derived foam cells, indicating that Lkn-1/CCL15 may 
play a role in the plaque rupture of the atherosclerotic lesions. 
Macrophages, which are abundant in ruptured atherosclerotic 
plaques, express multiple MMPs, weakening the plaque and 
making it rupture prone (Boyle, 2005). Among MMPs, MMP-9 
(92-kDa gelatinase B), which is a prevalent form expressed by 
activated macrophages and foam cells, is found in human 
coronary atherosclerotic lesions (Galis & Khatri, 2002; Paster-
kamp et al., 2000). We found that Lkn-1 significantly activated 
human THP-1 monocytes-derived macrophages and human 
PBMC-derived macrophages to release MMP-9 (Fig. 1A and 1B). 
It has been shown that the circulating levels of Lkn-1 are 
increased in plasma of atherosclerotic patients, and Lkn-1 
stimulates endothelial cells to release intracellular adhesion 
molecule-1 (Yu et al., 2004). Since MMP-9 is required for 
monocyte infiltration through endothelium from blood, Lkn1/ 
CCL15 action on macrophages to release MMP-9 may accelerate 
the recruitment of macrophages into the atherosclerotic lesions. 
It has been shown that the expression levels of chemokine 
genes such as monocyte chemoattractant protein-1 (MCP-1) and 
interleukin-8 (IL-8) are upregulated in human atherosclerotic 
lesions and they are associated with plaque rupture by activating 
endothelial cells and smooth muscle cells to release MMPs 
(Kodali et al., 2006; Reape et al., 1999; Sheikine et al., 2004; 
Shin  et al., 2002). Atherosclerotic lesions consist of mainly 
macrophages and lipid-laden foam cells, and thus excessive 
production of MMP-9 by Lkn-1/CCL15 from macrophages and 
macrophage-derived foam cells in the lesions may accelerate the 
destabilization and rupture of the fibrous cap of the athero-
sclerotic plaque. Our data demonstrated that Lkn-1 markedly 
enhanced the production of MMP-9 from macrophage-derived 
foam cells (Fig. 2). We have previously shown that proathero-
genic mediators enhance Lkn-1/CCL15 release from macro-136 Lkn-1/CCL15 enhances MMP-9 release 
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Fig. 1. Effect of Lkn-1 on the production of MMP-9 protein from human THP-1 
monocytic cells-derived macrophages, PBMC-derived macrophags, macro-
phages-derived foam cells. (A) Human THP-1 monocytic cells were plated at a 
density  of  5 × 10
5 cells/ml  in  the  medium  containing  PMA at 10
-7M  fo r 48  h to 
induce their differentiation into macrophages, and then the cells were treated with 
Lkn-1/CCL15 (100-300 ng/ml) for 24 h or 48 h. (B) Human peripheral blood monocytes 
were plated at a density of 5×10
5 cells/ml in the medium containing PMA at 10
-7M 
for  48  h  to  induce  their  differentiation  into  macrophages,  and  then  treated  with 
Lkn-1/CCL15 (100-300 ng/ml) for 24 h or 48 h. The gelatinolytic activities of MMP-9 
released into the conditioning culture medium were assayed by Gelatin Zymography 
described in the Materials and Methods. * P < 0.05, significantly different from the 
control  without  Lkn-1/CCL15  treatment.
Fig. 2. Effect of Lkn-1 on the production of MMP-9 protein from macro-
phages-derived foam cells. Human THP-1 cells were plated at a density of 5 ×
10
5  cells/ml  in  the  medium  containing  PMA  at  10
-7M  for  48  h  to  induce  their 
differentiation  into  macrophages.  THP-1  cells-derived  macrophages  were 
continuously treated with human oxidized LDL (25 μg/ml) for 4 days to prepare 
foam cells, and then the foam cells are treated with or without Lkn-1/CCL15 for 
16  h. The  gelatinolytic  activities  of  MMP-9  released  into  the  conditioning  culture 
medium  were  assayed  by  Gelatin  Zymography  described  in  the  Materials  and 
Methods. * P < 0.05, significantly different from the control without Lkn-1/CCL15 
treatment.
phages and macrophage-derived foam cells (Yu et al., 2004). 
Therefore, it can be postulated that macrophages and macro-
phage-derived foam cells in atherosclerotic lesions may enhance 
the local concentration of Lkn-1 in the lesions, and Lkn-1/CCL15 
subsequently stimulate the macrophages/foam cells per se to 
secrete MMP-9, indicating that Lkn-1/CCL15 action on macro-
phages and foam cells to release MMP-9 may contribute to 
plaque destabilization in the progression of atherosclerosis. 
In conclusion, Lkn-1/CCL15 enhanced MMP-9 protein secre-
tion from THP-1 monocytic cells-derived macrophages, human 
PBMC-derived macrophages, and THP-1 macrophage-derived 
foam cells in a dose dependent manner. Considering the associa-
tion of MMP-9 in plaque rupture, our findings suggest that 
Lkn-1/CCL15 could be associated with plaque destabilization in 
the progression of atherosclerosis. Lkn-1/CCL15 may be a useful 
target for the management of atherosclerosis. Further studies are 
needed to elucidate the inhibitory effect of phytochemicals or 
food factors on Lkn-1/CCL15 release from macrophages/foam 
cells. 
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